Apyx Medical CORP (APYX) 13F Ownership Report (Q2 2026)

APYX ranks #5410 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

69 institutions disclose a position in APYX, but none treat it as a major bet — even Archon Capital Management LLC, its most concentrated holder, allocates just 4.8% of its own portfolio to it.

Royce & Associates LP has added to its APYX position for two straight quarters, increasing it by $6.1M to reach $14.7M today.

Qube Research & Technologies Ltd has trimmed its APYX position for two straight quarters, cutting it by $275.6K while still holding $52.3K.

APYX is up 1% today, and institutions have been net buyers of $3.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

APYX reported a net loss of $8.6M over the trailing twelve months.

• Not yet profitable — net loss of $8.6M over the trailing twelve months
• Revenue grew 25.6% year over year
• Net income improved year over year, from -$17.3M to -$8.6M
• Operating cash flow was negative, using $8.0M in cash
• Current ratio of 5.00x — enough short-term assets to cover short-term liabilities
• Liabilities run 3.58x equity — a highly leveraged balance sheet worth noting